APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Receptor ROR-Gamma

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nuclear Receptor ROR-Gamma Market Outlook and Growth Opportunities 2026

19 December 2025208 pages

Choose your research edition.

Industry ResearchNuclear Receptor ROR-Gamma Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Receptor ROR-Gamma Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Nuclear Receptor ROR-Gamma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Receptor ROR-Gamma Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Receptor ROR-Gamma Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Nuclear Receptor ROR-Gamma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nuclear Receptor ROR-Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nuclear Receptor ROR-Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nuclear Receptor ROR-Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nuclear Receptor ROR-Gamma market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nuclear Receptor ROR-Gamma market include 4SC AG, Vitae Pharmaceuticals, Inc., Visionary Pharmaceuticals, Inc., Teijin Pharma Limited, Reata Pharmaceuticals, Inc., Phenex Pharmaceuticals AG, Nuevolution AB, Lead Pharma Holding B.V. and Karo Bio AB, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nuclear Receptor ROR-Gamma market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nuclear Receptor ROR-Gamma and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Receptor ROR-Gamma revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nuclear Receptor ROR-Gamma market.

Nuclear Receptor ROR-Gamma Segment by Company

4SC AG

Vitae Pharmaceuticals, Inc.

Visionary Pharmaceuticals, Inc.

Teijin Pharma Limited

Reata Pharmaceuticals, Inc.

Phenex Pharmaceuticals AG

Nuevolution AB

Lead Pharma Holding B.V.

Karo Bio AB

Hanmi Pharmaceuticals, Co. Ltd.

GlaxoSmithKline Plc

Genfit SA

Genentech, Inc.

Celgene Corporation

Bristol-Myers Squibb Company

Brickell Biotech, Inc.

Biogen, Inc.

Aurigene Discovery Technologies Limited

Arrien Pharmaceuticals, LLC

Advinus Therapeutics Ltd.

Nuclear Receptor ROR-Gamma Segment by Type

BBI-6000

GSK-2981278

INV-17

VPR-66

Others

Nuclear Receptor ROR-Gamma Segment by Application

Hospital

Clinic

Others

Nuclear Receptor ROR-Gamma Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nuclear Receptor ROR-Gamma status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nuclear Receptor ROR-Gamma key companies, revenue, market share, and recent developments.

3. To split the Nuclear Receptor ROR-Gamma breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nuclear Receptor ROR-Gamma market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nuclear Receptor ROR-Gamma significant trends, drivers, influence factors in global and regions.

6. To analyze Nuclear Receptor ROR-Gamma competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Receptor ROR-Gamma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Receptor ROR-Gamma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Receptor ROR-Gamma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Receptor ROR-Gamma industry.

Chapter 3: Detailed analysis of Nuclear Receptor ROR-Gamma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nuclear Receptor ROR-Gamma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nuclear Receptor ROR-Gamma in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nuclear Receptor ROR-Gamma Industry Trends Table 2. Nuclear Receptor ROR-Gamma Industry Drivers Table 3. Nuclear Receptor ROR-Gamma Industry Opportunities and Challenges Table 4. Nuclear Receptor ROR-Gamma Industry Restraints Table 5. Global Nuclear Receptor ROR-Gamma Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nuclear Receptor ROR-Gamma Revenue Share by Company (2021-2026) Table 7. Global Nuclear Receptor ROR-Gamma Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nuclear Receptor ROR-Gamma Key Company Manufacturing Base & Headquarters Table 9. Global Nuclear Receptor ROR-Gamma Company, Product Type & Application Table 10. Global Nuclear Receptor ROR-Gamma Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nuclear Receptor ROR-Gamma by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of BBI-6000 Table 15. Significant Companies of GSK-2981278 Table 16. Significant Companies of INV-17 Table 17. Significant Companies of VPR-66 Table 18. Significant Companies of Others Table 19. Global Nuclear Receptor ROR-Gamma Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Nuclear Receptor ROR-Gamma Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Nuclear Receptor ROR-Gamma Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Nuclear Receptor ROR-Gamma Sales Value Share by Type (2021-2026) Table 23. Global Nuclear Receptor ROR-Gamma Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Clinic Table 26. Significant Companies of Others Table 27. Global Nuclear Receptor ROR-Gamma Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nuclear Receptor ROR-Gamma Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nuclear Receptor ROR-Gamma Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nuclear Receptor ROR-Gamma Sales Value Share by Application (2021-2026) Table 31. Global Nuclear Receptor ROR-Gamma Sales Value Share by Application (2027-2032) Table 32. Global Nuclear Receptor ROR-Gamma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nuclear Receptor ROR-Gamma Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nuclear Receptor ROR-Gamma Sales Value Share by Region (2021-2026) Table 35. Global Nuclear Receptor ROR-Gamma Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nuclear Receptor ROR-Gamma Sales Value Share by Region (2027-2032) Table 37. Global Nuclear Receptor ROR-Gamma Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nuclear Receptor ROR-Gamma Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nuclear Receptor ROR-Gamma Sales Value Market Share by Country (2021-2026) Table 40. Global Nuclear Receptor ROR-Gamma Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nuclear Receptor ROR-Gamma Sales Value Market Share by Country (2027-2032) Table 42. 4SC AG Company Information Table 43. 4SC AG Business Overview Table 44. 4SC AG Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. 4SC AG Nuclear Receptor ROR-Gamma Product Portfolio Table 46. 4SC AG Recent Development Table 47. Vitae Pharmaceuticals, Inc. Company Information Table 48. Vitae Pharmaceuticals, Inc. Business Overview Table 49. Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 51. Vitae Pharmaceuticals, Inc. Recent Development Table 52. Visionary Pharmaceuticals, Inc. Company Information Table 53. Visionary Pharmaceuticals, Inc. Business Overview Table 54. Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 56. Visionary Pharmaceuticals, Inc. Recent Development Table 57. Teijin Pharma Limited Company Information Table 58. Teijin Pharma Limited Business Overview Table 59. Teijin Pharma Limited Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Teijin Pharma Limited Nuclear Receptor ROR-Gamma Product Portfolio Table 61. Teijin Pharma Limited Recent Development Table 62. Reata Pharmaceuticals, Inc. Company Information Table 63. Reata Pharmaceuticals, Inc. Business Overview Table 64. Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 66. Reata Pharmaceuticals, Inc. Recent Development Table 67. Phenex Pharmaceuticals AG Company Information Table 68. Phenex Pharmaceuticals AG Business Overview Table 69. Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Product Portfolio Table 71. Phenex Pharmaceuticals AG Recent Development Table 72. Nuevolution AB Company Information Table 73. Nuevolution AB Business Overview Table 74. Nuevolution AB Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Nuevolution AB Nuclear Receptor ROR-Gamma Product Portfolio Table 76. Nuevolution AB Recent Development Table 77. Lead Pharma Holding B.V. Company Information Table 78. Lead Pharma Holding B.V. Business Overview Table 79. Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Product Portfolio Table 81. Lead Pharma Holding B.V. Recent Development Table 82. Karo Bio AB Company Information Table 83. Karo Bio AB Business Overview Table 84. Karo Bio AB Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Karo Bio AB Nuclear Receptor ROR-Gamma Product Portfolio Table 86. Karo Bio AB Recent Development Table 87. Hanmi Pharmaceuticals, Co. Ltd. Company Information Table 88. Hanmi Pharmaceuticals, Co. Ltd. Business Overview Table 89. Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Product Portfolio Table 91. Hanmi Pharmaceuticals, Co. Ltd. Recent Development Table 92. GlaxoSmithKline Plc Company Information Table 93. GlaxoSmithKline Plc Business Overview Table 94. GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Product Portfolio Table 96. GlaxoSmithKline Plc Recent Development Table 97. Genfit SA Company Information Table 98. Genfit SA Business Overview Table 99. Genfit SA Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Genfit SA Nuclear Receptor ROR-Gamma Product Portfolio Table 101. Genfit SA Recent Development Table 102. Genentech, Inc. Company Information Table 103. Genentech, Inc. Business Overview Table 104. Genentech, Inc. Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Genentech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 106. Genentech, Inc. Recent Development Table 107. Celgene Corporation Company Information Table 108. Celgene Corporation Business Overview Table 109. Celgene Corporation Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Celgene Corporation Nuclear Receptor ROR-Gamma Product Portfolio Table 111. Celgene Corporation Recent Development Table 112. Bristol-Myers Squibb Company Company Information Table 113. Bristol-Myers Squibb Company Business Overview Table 114. Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Product Portfolio Table 116. Bristol-Myers Squibb Company Recent Development Table 117. Brickell Biotech, Inc. Company Information Table 118. Brickell Biotech, Inc. Business Overview Table 119. Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 121. Brickell Biotech, Inc. Recent Development Table 122. Biogen, Inc. Company Information Table 123. Biogen, Inc. Business Overview Table 124. Biogen, Inc. Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Biogen, Inc. Nuclear Receptor ROR-Gamma Product Portfolio Table 126. Biogen, Inc. Recent Development Table 127. Aurigene Discovery Technologies Limited Company Information Table 128. Aurigene Discovery Technologies Limited Business Overview Table 129. Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Product Portfolio Table 131. Aurigene Discovery Technologies Limited Recent Development Table 132. Arrien Pharmaceuticals, LLC Company Information Table 133. Arrien Pharmaceuticals, LLC Business Overview Table 134. Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Product Portfolio Table 136. Arrien Pharmaceuticals, LLC Recent Development Table 137. Advinus Therapeutics Ltd. Company Information Table 138. Advinus Therapeutics Ltd. Business Overview Table 139. Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Product Portfolio Table 141. Advinus Therapeutics Ltd. Recent Development Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Nuclear Receptor ROR-Gamma Product Image Figure 2. Global Nuclear Receptor ROR-Gamma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Receptor ROR-Gamma Market Size (2021-2032) & (US$ Million) Figure 4. Global Nuclear Receptor ROR-Gamma Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. BBI-6000 Image Figure 8. GSK-2981278 Image Figure 9. INV-17 Image Figure 10. VPR-66 Image Figure 11. Others Image Figure 12. Global Nuclear Receptor ROR-Gamma Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Nuclear Receptor ROR-Gamma Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Nuclear Receptor ROR-Gamma Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Clinic Image Figure 17. Others Image Figure 18. Global Nuclear Receptor ROR-Gamma Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nuclear Receptor ROR-Gamma Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nuclear Receptor ROR-Gamma Sales Value Share by Application (2021-2032) Figure 21. Global Nuclear Receptor ROR-Gamma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nuclear Receptor ROR-Gamma Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nuclear Receptor ROR-Gamma Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nuclear Receptor ROR-Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nuclear Receptor ROR-Gamma Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nuclear Receptor ROR-Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nuclear Receptor ROR-Gamma Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nuclear Receptor ROR-Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nuclear Receptor ROR-Gamma Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nuclear Receptor ROR-Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nuclear Receptor ROR-Gamma Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nuclear Receptor ROR-Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • BBI-6000
  • GSK-2981278
  • INV-17
  • VPR-66
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • 4SC AG
  • Vitae Pharmaceuticals, Inc.
  • Visionary Pharmaceuticals, Inc.
  • Teijin Pharma Limited
  • Reata Pharmaceuticals, Inc.
  • Phenex Pharmaceuticals AG
  • Nuevolution AB
  • Lead Pharma Holding B.V.
  • Karo Bio AB
  • Hanmi Pharmaceuticals, Co. Ltd.
  • GlaxoSmithKline Plc
  • Genfit SA
  • Genentech, Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Brickell Biotech, Inc.
  • Biogen, Inc.
  • Aurigene Discovery Technologies Limited
  • Arrien Pharmaceuticals, LLC
  • Advinus Therapeutics Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nuclear Receptor ROR-Gamma Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nuclear Receptor ROR-Gamma Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nuclear Receptor ROR-Gamma Market Dynamics
  1. 2.1 Nuclear Receptor ROR-Gamma Industry Trends
  2. 2.2 Nuclear Receptor ROR-Gamma Industry Drivers
  3. 2.3 Nuclear Receptor ROR-Gamma Industry Opportunities and Challenges
  4. 2.4 Nuclear Receptor ROR-Gamma Industry Restraints
3 Nuclear Receptor ROR-Gamma Market by Company
  1. 3.1 Global Nuclear Receptor ROR-Gamma Company Revenue Ranking in 2025
  2. 3.2 Global Nuclear Receptor ROR-Gamma Revenue by Company (2021-2026)
  3. 3.3 Global Nuclear Receptor ROR-Gamma Company Ranking (2024-2026)
  4. 3.4 Global Nuclear Receptor ROR-Gamma Company Manufacturing Base and Headquarters
  5. 3.5 Global Nuclear Receptor ROR-Gamma Company Product Type and Application
  6. 3.6 Global Nuclear Receptor ROR-Gamma Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nuclear Receptor ROR-Gamma Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nuclear Receptor ROR-Gamma Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nuclear Receptor ROR-Gamma Market by Type
  1. 4.1 Nuclear Receptor ROR-Gamma Type Introduction
  2. 4.1.1 BBI-6000
  3. 4.1.2 GSK-2981278
  4. 4.1.3 INV-17
  5. 4.1.4 VPR-66
  6. 4.1.5 Others
  7. 4.2 Global Nuclear Receptor ROR-Gamma Sales Value by Type
  8. 4.2.1 Global Nuclear Receptor ROR-Gamma Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Nuclear Receptor ROR-Gamma Sales Value by Type (2021-2032)
  10. 4.2.3 Global Nuclear Receptor ROR-Gamma Sales Value Share by Type (2021-2032)
5 Nuclear Receptor ROR-Gamma Market by Application
  1. 5.1 Nuclear Receptor ROR-Gamma Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Nuclear Receptor ROR-Gamma Sales Value by Application
  6. 5.2.1 Global Nuclear Receptor ROR-Gamma Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nuclear Receptor ROR-Gamma Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nuclear Receptor ROR-Gamma Sales Value Share by Application (2021-2032)
6 Nuclear Receptor ROR-Gamma Regional Value Analysis
  1. 6.1 Global Nuclear Receptor ROR-Gamma Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Receptor ROR-Gamma Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nuclear Receptor ROR-Gamma Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nuclear Receptor ROR-Gamma Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nuclear Receptor ROR-Gamma Sales Value (2021-2032)
  7. 6.3.2 North America Nuclear Receptor ROR-Gamma Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nuclear Receptor ROR-Gamma Sales Value (2021-2032)
  10. 6.4.2 Europe Nuclear Receptor ROR-Gamma Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nuclear Receptor ROR-Gamma Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nuclear Receptor ROR-Gamma Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nuclear Receptor ROR-Gamma Sales Value (2021-2032)
  16. 6.6.2 South America Nuclear Receptor ROR-Gamma Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nuclear Receptor ROR-Gamma Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nuclear Receptor ROR-Gamma Sales Value Share by Country, 2025 VS 2032
7 Nuclear Receptor ROR-Gamma Country-level Value Analysis
  1. 7.1 Global Nuclear Receptor ROR-Gamma Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nuclear Receptor ROR-Gamma Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nuclear Receptor ROR-Gamma Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nuclear Receptor ROR-Gamma Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nuclear Receptor ROR-Gamma Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nuclear Receptor ROR-Gamma Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nuclear Receptor ROR-Gamma Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 4SC AG
  2. 8.1.1 4SC AG Company Information
  3. 8.1.2 4SC AG Business Overview
  4. 8.1.3 4SC AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  5. 8.1.4 4SC AG Nuclear Receptor ROR-Gamma Product Portfolio
  6. 8.1.5 4SC AG Recent Developments
  7. 8.2 Vitae Pharmaceuticals, Inc.
  8. 8.2.1 Vitae Pharmaceuticals, Inc. Company Information
  9. 8.2.2 Vitae Pharmaceuticals, Inc. Business Overview
  10. 8.2.3 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  12. 8.2.5 Vitae Pharmaceuticals, Inc. Recent Developments
  13. 8.3 Visionary Pharmaceuticals, Inc.
  14. 8.3.1 Visionary Pharmaceuticals, Inc. Company Information
  15. 8.3.2 Visionary Pharmaceuticals, Inc. Business Overview
  16. 8.3.3 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  18. 8.3.5 Visionary Pharmaceuticals, Inc. Recent Developments
  19. 8.4 Teijin Pharma Limited
  20. 8.4.1 Teijin Pharma Limited Company Information
  21. 8.4.2 Teijin Pharma Limited Business Overview
  22. 8.4.3 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Product Portfolio
  24. 8.4.5 Teijin Pharma Limited Recent Developments
  25. 8.5 Reata Pharmaceuticals, Inc.
  26. 8.5.1 Reata Pharmaceuticals, Inc. Company Information
  27. 8.5.2 Reata Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  30. 8.5.5 Reata Pharmaceuticals, Inc. Recent Developments
  31. 8.6 Phenex Pharmaceuticals AG
  32. 8.6.1 Phenex Pharmaceuticals AG Company Information
  33. 8.6.2 Phenex Pharmaceuticals AG Business Overview
  34. 8.6.3 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Product Portfolio
  36. 8.6.5 Phenex Pharmaceuticals AG Recent Developments
  37. 8.7 Nuevolution AB
  38. 8.7.1 Nuevolution AB Company Information
  39. 8.7.2 Nuevolution AB Business Overview
  40. 8.7.3 Nuevolution AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nuevolution AB Nuclear Receptor ROR-Gamma Product Portfolio
  42. 8.7.5 Nuevolution AB Recent Developments
  43. 8.8 Lead Pharma Holding B.V.
  44. 8.8.1 Lead Pharma Holding B.V. Company Information
  45. 8.8.2 Lead Pharma Holding B.V. Business Overview
  46. 8.8.3 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Product Portfolio
  48. 8.8.5 Lead Pharma Holding B.V. Recent Developments
  49. 8.9 Karo Bio AB
  50. 8.9.1 Karo Bio AB Company Information
  51. 8.9.2 Karo Bio AB Business Overview
  52. 8.9.3 Karo Bio AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Karo Bio AB Nuclear Receptor ROR-Gamma Product Portfolio
  54. 8.9.5 Karo Bio AB Recent Developments
  55. 8.10 Hanmi Pharmaceuticals, Co. Ltd.
  56. 8.10.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
  57. 8.10.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
  58. 8.10.3 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
  60. 8.10.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
  61. 8.11 GlaxoSmithKline Plc
  62. 8.11.1 GlaxoSmithKline Plc Company Information
  63. 8.11.2 GlaxoSmithKline Plc Business Overview
  64. 8.11.3 GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Product Portfolio
  66. 8.11.5 GlaxoSmithKline Plc Recent Developments
  67. 8.12 Genfit SA
  68. 8.12.1 Genfit SA Company Information
  69. 8.12.2 Genfit SA Business Overview
  70. 8.12.3 Genfit SA Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Genfit SA Nuclear Receptor ROR-Gamma Product Portfolio
  72. 8.12.5 Genfit SA Recent Developments
  73. 8.13 Genentech, Inc.
  74. 8.13.1 Genentech, Inc. Company Information
  75. 8.13.2 Genentech, Inc. Business Overview
  76. 8.13.3 Genentech, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Genentech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  78. 8.13.5 Genentech, Inc. Recent Developments
  79. 8.14 Celgene Corporation
  80. 8.14.1 Celgene Corporation Company Information
  81. 8.14.2 Celgene Corporation Business Overview
  82. 8.14.3 Celgene Corporation Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Celgene Corporation Nuclear Receptor ROR-Gamma Product Portfolio
  84. 8.14.5 Celgene Corporation Recent Developments
  85. 8.15 Bristol-Myers Squibb Company
  86. 8.15.1 Bristol-Myers Squibb Company Company Information
  87. 8.15.2 Bristol-Myers Squibb Company Business Overview
  88. 8.15.3 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Product Portfolio
  90. 8.15.5 Bristol-Myers Squibb Company Recent Developments
  91. 8.16 Brickell Biotech, Inc.
  92. 8.16.1 Brickell Biotech, Inc. Company Information
  93. 8.16.2 Brickell Biotech, Inc. Business Overview
  94. 8.16.3 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  96. 8.16.5 Brickell Biotech, Inc. Recent Developments
  97. 8.17 Biogen, Inc.
  98. 8.17.1 Biogen, Inc. Company Information
  99. 8.17.2 Biogen, Inc. Business Overview
  100. 8.17.3 Biogen, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Biogen, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
  102. 8.17.5 Biogen, Inc. Recent Developments
  103. 8.18 Aurigene Discovery Technologies Limited
  104. 8.18.1 Aurigene Discovery Technologies Limited Company Information
  105. 8.18.2 Aurigene Discovery Technologies Limited Business Overview
  106. 8.18.3 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Product Portfolio
  108. 8.18.5 Aurigene Discovery Technologies Limited Recent Developments
  109. 8.19 Arrien Pharmaceuticals, LLC
  110. 8.19.1 Arrien Pharmaceuticals, LLC Company Information
  111. 8.19.2 Arrien Pharmaceuticals, LLC Business Overview
  112. 8.19.3 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Product Portfolio
  114. 8.19.5 Arrien Pharmaceuticals, LLC Recent Developments
  115. 8.20 Advinus Therapeutics Ltd.
  116. 8.20.1 Advinus Therapeutics Ltd. Company Information
  117. 8.20.2 Advinus Therapeutics Ltd. Business Overview
  118. 8.20.3 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
  120. 8.20.5 Advinus Therapeutics Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst